Alembic Pharma

Neutral Alembic Pharma; target of Rs 990: Motilal Oswal

Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 990 in its research report dated August 05, 2025.

Hold Alembic Pharma: target of Rs 900: ICICI Securities

ICICI Securities recommended hold rating on Alembic Pharma with a target price of Rs 900 in its research report dated August 06, 2025.

Stocks to Watch Today: Torrent Pharma, JB Chemicals, Jyoti CNC, BHEL, Alembic Pharma, Waaree Energies, Prestige Estates, Hind Rectifiers in focus on 30 June

Stocks to Watch, 30 June: Stocks like Torrent Pharmaceuticals, JB Chemicals and Pharmaceuticals, Jyoti CNC Automation, BHEL, Alembic Pharma, Waaree Energies, Prestige Estates Projects, Bharti Airtel, Le Lavoir, Reliance Industries, and Hind Rectifiers will be in focus on June 30.

Neutral Alembic Pharma; target of Rs 930: Motilal Oswal

Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 930 in its research report dated May 06, 2025.

Alembic Pharma shares gain on EIR from USFDA for Panelav facility

Alembic Pharma Share Price | A meeting of board of directors of the company will be held on May 6, 2025, to consider audited financialrResults of the company for the quarter and financial year ended 31st March, 2025 and recommend dividend on equity shares, if any, for the financial year ended 31st March, 2025.

Stocks To Watch: Alembic Pharma, BHEL, Zydus Life, Wipro In Focus | February 17

In today's stock market update for February 17, we highlight key stocks to watch: Wipro, which appointed Amit Kumar as Managing Partner and Global Head of Consulting; BHEL, which secured a Letter of Intent for a thermal power project; and Alembic Pharma, which received a Voluntary Action Indicated classification from the US FDA for its Jarod facility. Zydus Lifesciences passed a successful US FDA inspection with no observations at its Ambernath site. Meanwhile, Ujjivan Small Finance Bank and Shriram Finance face RBI penalties for non-compliance with loan and KYC regulations. Stay tuned for more market insights!

Hold Alembic Pharma: target of Rs 925: ICICI Securities

ICICI Securities recommended hold rating on Alembic Pharma with a target price of Rs 925 in its research report dated February 04, 2025.

Neutral Alembic Pharma; target of Rs 970: Motilal Oswal

Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 970 in its research report dated February 03, 2025.

Neutral Alembic Pharma; target of Rs 1110: Motilal Oswal

Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 1110 in its research report dated November 07, 2024.

Alembic Pharma zooms to record high after USFDA greenlights Gujarat facility

The regulatory clearance for Alembic Pharma's Gujarat facility came without any observations. The USFDA had inspected the facility on October 7-8.

Alembic Pharma jumps 4% on US FDA approves anti-seizure drug worth $163 million

The estimated market value for Lamotrigine Extended-Release Tablets is approximately $163 million for the year ending June 2024, according to IQVIA.

Alembic Pharma gets USFDA nod for generic drug used to treat schizophrenia

Paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg have an estimated market size of $48 million for 12 months ended June 2024.

Alembic Pharma gets USFDA nod for cancer drug

Nelarabine is used in treating T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma in patients who do not respond or have relapsed after at least two chemotherapy regimens.

Alembic Pharma stock rallies 5% after firm receives USFDA tentative approval for Bosutinib tablets

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosutinib Tablets.

Alembic Pharma gets USFDA nod to market heart failure drug

The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Alembic said in a regulatory filing.